NT2

Neurotech International is a clinical-stage biopharmaceutical company focused on the development of novel therapies for neurodevelopmental and neuroinflammatory disorders. The company's lead program, NTI164, is a proprietary cannabis-derived drug formulation with low THC and high concentrations of minor cannabinoids like CBDA and CBGA, designed to modulate neuroinflammation. Neurotech is currently advancing clinical trials for indications including Autism Spectrum Disorder (ASD), PANDAS/PANS, and Cerebral Palsy. Additionally, the company developed the Mente device, a neurofeedback technology aimed at managing children with ASD, though its primary focus has shifted toward its pharmaceutical pipeline.